The Readout Loud
STAT
Add to My Podcasts
Episodes
About
Reviews
Promote
Episode 124: Pharma's lobbying dollars, Alnylam's future, and diversity in Covid-19 studies
26 minutes
Posted Aug 13, 2020 at 8:01 pm.
0:00
26:48
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
Is pharma scared of Kamala Harris? Are there second acts in biotech? And why don't Covid-19 trials look more diverse?
Previous
Episode 123: Steven Salzberg's Twitter debate, a health tech mega-deal & Covid-19 vaccine prices
Next
Episode 125: Shocking FDA rejections, a longevity science setback & Derek Lowe on Covid-19 vaccines
← See all 424 episodes of The Readout Loud
